China Pharma Holdings

CPHI

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$8.10

+7.19 (+790.11%)

Market Cap

$25.7M

Exchange

New York Stock Exchange American

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count falling — buybacks

−7.0% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 4.6M (2021) → 4.3M (2025)

China Pharma Holdings is a small pharmaceutical company based in China that makes and sells generic and specialty drugs. Its products include traditional Chinese medicines and Western-style pharmaceuticals, sold mainly to hospitals, clinics, and distributors across China. The company operates manufacturing facilities in Hainan province and targets the domestic Chinese healthcare market.

The company earns revenue by selling finished drug products directly to healthcare institutions and wholesale distributors. It is a very small player in China's crowded generic drug industry, with a market cap near zero and no meaningful competitive moat against larger domestic rivals. The financials are deeply troubled — negative gross and operating margins signal the company is losing money on every dollar of sales — and the primary risk is whether it can restructure operations and return to profitability before running out of resources.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-13.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-50.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$280,901/ year

→ Flat (-1% vs prior year)

6.8% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

26.4%ownership

Insiders own a meaningful stake in the company

Cash Runway

~19 months

$348,474 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Adequate runway but may need to raise capital within 2 years

Revenue declining

China Pharma Holdings's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-54.9%

Thin — -54.9% gross margin

Operating Margin

-113.6%

Losing money on operations — -113.6%

ROCE

-2.7%

Weak — -2.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-7.1%

Shrinking sales (-7.1% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

3.4%

Thin free cash flow (3.4%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.10

Conservative — low debt load (0.10)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial